Home » SeqWright to Handle DNA Screening/Genotyping for Third Wave's HPV Trials

SeqWright to Handle DNA Screening/Genotyping for Third Wave's HPV Trials

Jan 04, 2007
NEW YORK (GenomeWeb News) — SeqWright today said it will perform all of the sequencing and analysis for a set of clinical trials being conducted by Third Wave Technologies.
 
Third Wave is developing two in vitro molecular assays and a genotyping test to screen for human papillomavirus, which has been identified as the cause of approximately 70 percent of cervical cancer cases, SeqWright said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

What's Popular?

In Clinical Sequencing

  1. Survey Finds QC Best Practices in Clinical Genomics Still Developing

  2. Families Declining Enrollment in BabySeq Cite Lack of Interest in Research, Logistical Challenges

  3. Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.